Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.

International journal of environmental research and public health·2020
Same author

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

British journal of haematology·2019
Same author

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Same author

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

The Lancet. Haematology·2018
Same author

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

The Lancet. Haematology·2018
Same author

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2018
Same journal

Fulminant haemophagocytic lymphohistiocytosis revealing an unexpected bone marrow pathogen.

The Lancet. Haematology·2026
Same journal

A US perspective on optimising the inpatient classical haematology consultation service.

The Lancet. Haematology·2026
Same journal

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same journal

Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.

The Lancet. Haematology·2026
Same journal

Exhibition: sharing the history of blood through patients' stories.

The Lancet. Haematology·2026
Same journal

Essential but neglected: securing the global supply of human hyperimmune immunoglobulins.

The Lancet. Haematology·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K

Diffuse large B-cell lymphoma: to maintain or not?

Bertrand Coiffier1

  • 1Department of Hematology, Hospices Civils de Lyon, Lyon, France.

The Lancet. Haematology
|February 22, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

Related Experiment Videos

Last Updated: Mar 7, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K